Dashboard
Manage Tickers

ASRT Assertio Holdings, Inc.

Nasdaq assertiotx.com


$ 0.82 $ 0.00 (0 %)    

Thursday, 23-Oct-2025 11:32:31 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 609.17 $ 0.00 (0 %)
DIA $ 466.53 $ 0.00 (0 %)
SPY $ 670.27 $ 0.00 (0 %)
TLT $ 91.50 $ 0.00 (0 %)
GLD $ 381.32 $ 0.00 (0 %)
$ 0.81
$ 0.81
$ 0.81 x 1,500
$ 0.82 x 1,600
$ 0.81 - $ 0.82
$ 0.51 - $ 1.12
184,320
na
77.95M
$ 1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-12-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-06-2024 03-31-2024 10-Q
7 03-11-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-08-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-10-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-12-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

assertio-presents-data-on-sympazan-showing-how-it-is-being-used-in-daily-clinical-practice-to-treat-patients-with-lennox-gastaut-syndrome
Assertio Presents Data On SYMPAZAN Showing...
09/15/2025 13:04:10

New data show how Sympazan is being used in daily clinical practice to treat patients with Lennox-Gastaut Syndrome (LGS), a sev...

assertio-holdings-will-present-new-data-for-sympazan-clobazam-at-the-annual-meeting-of-the-american-neurological-association
Assertio Holdings Will Present New Data Fo...
09/10/2025 11:32:20

Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive ...

reuters-reports-fda-saying-assertio-specialty-pharmaceuticals-discontinues-manufacturing-of-otrexup-injection
Reuters Reports FDA Saying Assertio Specia...
08/29/2025 13:58:45

hc-wainwright--co-maintains-buy-on-assertio-holdings-lowers-price-target-to-3
HC Wainwright & Co. Maintains Buy on Asser...
08/12/2025 12:08:31

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Assertio Holdings (NASDAQ:ASRT) with a Buy and lowers the price...

assertio-holdings-narrows-fy2025-sales-guidance-from-10800m-12300m-to-10800m-11800m-vs-11372m-est
Assertio Holdings Narrows FY2025 Sales Gui...
08/11/2025 20:08:05

Assertio Holdings (NASDAQ:ASRT) narrows FY2025 sales outlook from $108.00 million-$123.00 million to $108.00 million-$118.00 mi...

assertio-holdings-q2-adj-eps-002-beats-008-estimate-sales-2922m-beat-2786m-estimate
Assertio Holdings Q2 Adj. EPS $0.02 Beats ...
08/11/2025 20:07:07

Assertio Holdings (NASDAQ:ASRT) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0...

Core News & Articles
Earnings Scheduled For August 11, 2025
08/11/2025 08:32:28

assertio-holdings-earnings-preview
Assertio Holdings Earnings Preview
08/08/2025 20:08:08

hc-wainwright--co-reiterates-buy-on-assertio-holdings-maintains-35-price-target
HC Wainwright & Co. Reiterates Buy on Asse...
05/19/2025 11:30:36

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Assertio Holdings (NASDAQ:ASRT) with a Buy and maintains $3.5 ...

assertio-holdings-q1-adj-eps-004-beats-006-estimate-sales-2649m-miss-2752m-estimate
Assertio Holdings Q1 Adj. EPS $(0.04) Beat...
05/12/2025 20:03:28

Assertio Holdings (NASDAQ:ASRT) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0...

Core News & Articles
Earnings Scheduled For May 12, 2025
05/12/2025 08:32:31

a-look-at-assertio-holdingss-upcoming-earnings-report
A Look at Assertio Holdings's Upcoming Ear...
05/09/2025 20:04:41

hc-wainwright--co-maintains-buy-on-assertio-holdings-lowers-price-target-to-35
HC Wainwright & Co. Maintains Buy on Asser...
03/19/2025 10:50:11

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Assertio Holdings (NASDAQ:ASRT) with a Buy and lowers the price...

assertio-holdings-sees-fy25-sales-108m-123m-vs-123686m-est
Assertio Holdings Sees FY25 Sales $108M-$1...
03/12/2025 20:18:49

assertio-holdings-q4-2024-adj-eps-003-beats-004-estimate-sales-32182m-beat-28674m-estimate
Assertio Holdings Q4 2024 Adj. EPS $(0.03)...
03/12/2025 20:17:16

Assertio Holdings (NASDAQ:ASRT) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0...

earnings-scheduled-for-march-12-2025
Earnings Scheduled For March 12, 2025
03/12/2025 08:32:26

hc-wainwright--co-reiterates-buy-on-assertio-holdings-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Asse...
12/16/2024 12:11:09

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Assertio Holdings (NASDAQ:ASRT) with a Buy and maintains $4 pr...

assertio-announces-results-of-a-clinical-trial-investigating-the-utility-of-rolvedon-injection-when-dosed-the-same-day-of-chemotherapy-for-patients-with-early-stage-breast-cancer
Assertio Announces Results Of A Clinical T...
12/13/2024 13:03:42

Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensiv...

hc-wainwright--co-reiterates-buy-on-assertio-holdings-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Asse...
11/25/2024 13:01:12

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Assertio Holdings (NASDAQ:ASRT) with a Buy and maintains $4 pr...

assertio-holdings-q3-2024-adj-eps-003-beats-005-estimate-sales-29204m-beat-28869m-estimate
Assertio Holdings Q3 2024 Adj. EPS $0.03 B...
11/11/2024 21:04:45

Assertio Holdings (NASDAQ:ASRT) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION